DK3120868T3 - Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer - Google Patents

Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer Download PDF

Info

Publication number
DK3120868T3
DK3120868T3 DK16179174.4T DK16179174T DK3120868T3 DK 3120868 T3 DK3120868 T3 DK 3120868T3 DK 16179174 T DK16179174 T DK 16179174T DK 3120868 T3 DK3120868 T3 DK 3120868T3
Authority
DK
Denmark
Prior art keywords
tumors
immunotherapy
variety
hitherto unknown
including nerve
Prior art date
Application number
DK16179174.4T
Other languages
English (en)
Inventor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Application granted granted Critical
Publication of DK3120868T3 publication Critical patent/DK3120868T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK16179174.4T 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer DK3120868T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP08017921.1A EP2172212B1 (en) 2008-10-01 2008-10-13 Novel immunotherapy against several tumors including neuronal and brain tumors
US10592808P 2008-10-16 2008-10-16
EP16165070.0A EP3069728B1 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors

Publications (1)

Publication Number Publication Date
DK3120868T3 true DK3120868T3 (da) 2020-06-22

Family

ID=40342382

Family Applications (12)

Application Number Title Priority Date Filing Date
DK08017305T DK2172211T3 (da) 2008-10-01 2008-10-01 Sammensætning af tumorassocierede peptider og relateret anticancervaccine til behandling af glioblastom (GBM) og andre cancertyper
DK08017921.1T DK2172212T3 (da) 2008-10-01 2008-10-13 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK09778750.1T DK2341927T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK16179241.1T DK3111952T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179192.6T DK3120869T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179169.4T DK3132801T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16165070.0T DK3069728T3 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors
DK09778749.3T DK2331118T5 (en) 2008-10-01 2009-09-28 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
DK16179214.8T DK3124043T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179174.4T DK3120868T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179226.2T DK3120870T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179163.7T DK3106175T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer

Family Applications Before (9)

Application Number Title Priority Date Filing Date
DK08017305T DK2172211T3 (da) 2008-10-01 2008-10-01 Sammensætning af tumorassocierede peptider og relateret anticancervaccine til behandling af glioblastom (GBM) og andre cancertyper
DK08017921.1T DK2172212T3 (da) 2008-10-01 2008-10-13 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK09778750.1T DK2341927T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK16179241.1T DK3111952T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179192.6T DK3120869T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179169.4T DK3132801T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16165070.0T DK3069728T3 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors
DK09778749.3T DK2331118T5 (en) 2008-10-01 2009-09-28 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
DK16179214.8T DK3124043T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK16179226.2T DK3120870T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179163.7T DK3106175T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer

Country Status (25)

Country Link
US (19) US8318677B2 (da)
EP (12) EP2172211B1 (da)
JP (10) JP5855940B2 (da)
KR (6) KR102392070B1 (da)
CN (3) CN106986919A (da)
AU (2) AU2009300088B2 (da)
BR (2) BRPI0920791B8 (da)
CA (9) CA2936868C (da)
CY (11) CY1116302T1 (da)
DK (12) DK2172211T3 (da)
EA (3) EA023378B1 (da)
ES (12) ES2536465T3 (da)
HK (2) HK1159526A1 (da)
HR (12) HRP20201025T8 (da)
HU (11) HUE031030T2 (da)
LT (10) LT2172212T (da)
MX (3) MX338294B (da)
NZ (4) NZ603016A (da)
PL (12) PL2172211T3 (da)
PT (12) PT2172211E (da)
RS (12) RS53782B1 (da)
SI (12) SI2172211T1 (da)
TR (2) TR201900809T4 (da)
UA (3) UA103202C2 (da)
WO (2) WO2010037514A2 (da)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
WO2009015843A1 (en) * 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
ES2342506T3 (es) * 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
ES2722799T3 (es) * 2010-08-24 2019-08-16 Univ Pittsburgh Commonwealth Sys Higher Education Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
AU2011344652B2 (en) * 2010-12-14 2015-11-19 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
JP2014526517A (ja) * 2011-09-14 2014-10-06 ノースウェスタン ユニバーシティ 血液脳関門を通過することができるナノ抱合体
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
KR20150018765A (ko) 2012-01-20 2015-02-24 데니스 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
US10485858B2 (en) 2012-05-16 2019-11-26 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
PT3456339T (pt) 2013-08-05 2021-12-09 Immatics Biotechnologies Gmbh Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc
TWI777194B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
DK3689899T3 (da) 2014-04-25 2021-11-22 2Seventy Bio Inc Kimære mnd-promotor-antigenreceptorer
WO2015182668A1 (ja) * 2014-05-28 2015-12-03 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
CN111394317A (zh) 2014-06-06 2020-07-10 蓝鸟生物公司 改善的t细胞组合物
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
AU2014410466B2 (en) * 2014-11-06 2019-09-12 Ose Immunotherapeutics Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
SI3626731T1 (sl) * 2014-12-23 2021-12-31 Immatics Biotechnologies Gmbh Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CR20230131A (es) * 2015-05-06 2023-06-23 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497)
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3650043A3 (en) 2015-06-09 2020-07-29 The Board of Regents of the University of Oklahoma Compositions and treatments for haemophilus influenzae
MX2017016931A (es) 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MY191654A (en) 2015-07-01 2022-07-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20231014A1 (es) * 2015-07-06 2023-07-05 Immatics Biotechnologies Gmbh Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI782433B (zh) 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017040885A1 (en) 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
WO2017123996A1 (en) 2016-01-15 2017-07-20 City Of Hope Targeting glioblastoma stem cells through the tlx-tet3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN109620949A (zh) * 2016-03-13 2019-04-16 曹帅 一种用于治疗骨癌的药物组合物
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
HUE060725T2 (hu) 2016-03-16 2023-04-28 Immatics Biotechnologies Gmbh Transzfektált T-sejtek és T-sejt receptorok daganatok ellen alkalmazott immunterápiában történõ használatra
PE20181896A1 (es) * 2016-04-06 2018-12-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide agua (lma) y otros tipos de cancer
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
CN110022889A (zh) * 2016-10-03 2019-07-16 渥太华医院研究所 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
MX2019004692A (es) 2017-01-06 2019-11-08 Eutilex Co Ltd Anticuerpos 4-1bb anti-humano y usos de los mismos.
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) * 2017-02-28 2018-08-30 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
TW201907937A (zh) * 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
AU2018385759B2 (en) 2017-12-14 2021-10-21 Flodesign Sonics, Inc. Acoustic transducer driver and controller
EP3724327A4 (en) * 2017-12-14 2022-01-12 EZY Biotech LLC SUBJECT-SPECIFIC TUMOR-INHIBITING CELLS AND THEIR USE
PL3773689T3 (pl) * 2018-04-11 2023-03-13 Enterome S.A. Peptydy antygenowe do zapobiegania i leczenia raka
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
GB2617512B (en) * 2019-04-05 2023-12-27 Earli Inc Improved methods and compositions for synthetic biomarkers
JP7150289B2 (ja) 2019-05-28 2022-10-11 ペイジ．エーアイ インコーポレイテッド デジタル病理学のための処理された画像に関するスライドを調製するために画像を処理するためのシステムおよび方法
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113621025A (zh) * 2020-03-18 2021-11-09 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
US11913023B2 (en) 2020-03-31 2024-02-27 Walking Fish Therapeutics, Inc. Modified B cells and methods of use thereof
KR20230006821A (ko) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 변형 b 세포 및 이의 사용 방법
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
KR20220022021A (ko) 2020-08-14 2022-02-23 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4203994A1 (en) * 2020-08-28 2023-07-05 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
WO1998003197A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1998031797A1 (en) 1997-01-15 1998-07-23 Zymogenetics, Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
JPH11507845A (ja) * 1997-02-13 1999-07-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経細胞付着分子スプライシング変種
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6682928B2 (en) * 1997-12-02 2004-01-27 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO1999055380A1 (en) * 1998-04-27 1999-11-04 Pacific Northwest Cancer Foundation Nr-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC USES FOR TUMORS
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
CA2395872A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020168711A1 (en) * 2000-01-31 2002-11-14 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1356048A2 (en) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1379879A2 (en) * 2000-12-08 2004-01-14 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of alzheimer's disease
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
AU2003298984A1 (en) * 2002-12-27 2004-08-23 Shenzhen Tsinghua Yuanxing Bio-Pharm Science And Technology Co., Ltd. Method of preparing a vaccine and anti-tumor vaccines
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
EP1712620A4 (en) * 2004-01-23 2008-05-28 Greenpeptide Co Ltd PEPTIDE FROM EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) * 2004-08-27 2006-03-09 Northeastern University Comprehensive characterization of complex proteins at trace levels
EP1642905B1 (en) * 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
CA2600898C (en) * 2004-12-07 2016-08-23 Toray Industries, Inc. Novel cancer antigen peptide and the use thereof
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
DK1760089T3 (da) * 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
DE602005020047D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
EP2089423B1 (en) * 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
EP2164859A4 (en) * 2007-03-06 2012-06-06 Iterative Therapeutics Inc METHODS AND COMPOSITIONS USING POLYMERIC IMMUNOGLOBULIN HYBRID PROTEINS
EP2280731A1 (en) * 2008-04-09 2011-02-09 Technion Research and Development Foundation, Ltd. Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ES2342506T3 (es) * 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CN114057895A (zh) * 2014-05-28 2022-02-18 诺诺公司 TAT-NR2B9c的氯盐
EA201892333A1 (ru) * 2016-04-21 2019-03-29 Имматикс Байотекнолоджиз Гмбх Иммунотерапия меланомы и других видов рака
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)

Also Published As

Publication number Publication date
DK3106175T3 (da) 2020-06-22
RS60338B1 (sr) 2020-07-31
HRP20200110T1 (hr) 2020-05-15
JP2017018101A (ja) 2017-01-26
PT3132801T (pt) 2020-02-04
US8119139B2 (en) 2012-02-21
PL3120868T3 (pl) 2020-08-24
CA2739384C (en) 2017-05-02
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
CA2936924A1 (en) 2010-04-08
PL2331118T3 (pl) 2017-05-31
EP2172212A3 (en) 2010-04-14
RS55531B1 (sr) 2017-05-31
MX2011003539A (es) 2011-06-20
US20190010190A1 (en) 2019-01-10
PL3132801T3 (pl) 2020-06-15
CY1121258T1 (el) 2020-05-29
US20120141517A1 (en) 2012-06-07
DK3069728T3 (en) 2019-02-25
US11208434B2 (en) 2021-12-28
PT3124043T (pt) 2020-05-12
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
US20160376314A1 (en) 2016-12-29
PL2172211T3 (pl) 2015-05-29
ES2536465T3 (es) 2015-05-25
US20160376313A1 (en) 2016-12-29
CA2936869A1 (en) 2010-04-08
US20160376315A1 (en) 2016-12-29
DK2331118T5 (en) 2017-06-19
HUE031030T2 (en) 2017-06-28
PT3120870T (pt) 2020-07-01
JP5753783B2 (ja) 2015-07-22
DK3132801T3 (da) 2020-02-10
DK2172212T3 (da) 2016-12-19
JP2017000148A (ja) 2017-01-05
HUE050428T2 (hu) 2020-12-28
EP3120869A1 (en) 2017-01-25
RS55543B1 (sr) 2017-05-31
HUE042115T2 (hu) 2019-06-28
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
DK3120869T3 (da) 2020-08-10
CY1118702T1 (el) 2017-07-12
HRP20182151T1 (hr) 2019-02-08
LT3132801T (lt) 2020-02-10
PT3120868T (pt) 2020-07-16
CY1122913T1 (el) 2021-10-29
SI2331118T1 (sl) 2017-01-31
EP3120870A1 (en) 2017-01-25
ES2584245T3 (es) 2016-09-26
EP2341927B1 (en) 2016-05-04
EP2331118A1 (en) 2011-06-15
BRPI0920791B8 (pt) 2022-02-15
HRP20201228T1 (hr) 2021-02-05
PL3120870T3 (pl) 2020-07-27
JP2017023136A (ja) 2017-02-02
KR20200085381A (ko) 2020-07-14
CA2739384A1 (en) 2010-04-08
CA2936924C (en) 2019-07-16
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
BRPI0920759A2 (pt) 2016-03-08
EP2172211A1 (en) 2010-04-07
US20130309193A1 (en) 2013-11-21
US10047123B2 (en) 2018-08-14
US20210261614A1 (en) 2021-08-26
WO2010037513A1 (en) 2010-04-08
KR20110074894A (ko) 2011-07-04
EP3106175A1 (en) 2016-12-21
CA2936870C (en) 2019-11-26
SI3111952T1 (sl) 2019-01-31
PL3124043T3 (pl) 2020-07-27
CY1121098T1 (el) 2019-12-11
CN102170901B (zh) 2015-01-07
CY1116302T1 (el) 2017-02-08
HUE047365T2 (hu) 2020-04-28
US10046037B2 (en) 2018-08-14
SI3120870T1 (sl) 2020-08-31
CA2936868A1 (en) 2010-04-08
HK1159526A1 (zh) 2012-08-03
EP2341927A2 (en) 2011-07-13
DK3124043T3 (da) 2020-05-04
NZ624533A (en) 2015-09-25
BRPI0920791A2 (pt) 2019-12-10
HUE041446T2 (hu) 2019-05-28
US20150125478A1 (en) 2015-05-07
HRP20160915T1 (hr) 2016-10-07
UA110599C2 (uk) 2016-01-25
WO2010037514A2 (en) 2010-04-08
JP6150859B2 (ja) 2017-06-21
US20170326217A1 (en) 2017-11-16
CA2936869C (en) 2019-08-06
MX338294B (es) 2016-04-11
MX2011003540A (es) 2011-06-20
AU2009300087A1 (en) 2010-04-08
TR201900809T4 (tr) 2019-02-21
NZ603016A (en) 2014-05-30
KR20110082155A (ko) 2011-07-18
US11136352B2 (en) 2021-10-05
HRP20201015T1 (hr) 2020-10-16
PT2341927T (pt) 2016-08-02
JP6214066B2 (ja) 2017-10-18
KR101756488B1 (ko) 2017-07-11
US9993540B2 (en) 2018-06-12
SI2172212T1 (sl) 2016-12-30
EP2172212A2 (en) 2010-04-07
PT2172212T (pt) 2016-12-22
EA201401104A1 (ru) 2015-05-29
US8961985B2 (en) 2015-02-24
HRP20190202T1 (hr) 2019-03-22
CA2936920C (en) 2019-12-03
RS55043B1 (sr) 2016-12-30
EP3124043B1 (en) 2020-04-29
US8318677B2 (en) 2012-11-27
US20160355550A1 (en) 2016-12-08
HRP20161504T1 (hr) 2016-12-30
EP3120868A1 (en) 2017-01-25
US8895514B2 (en) 2014-11-25
HRP20150223T1 (hr) 2015-06-05
SI3069728T1 (sl) 2019-03-29
ES2612466T3 (es) 2017-05-17
HUE029360T2 (en) 2017-02-28
KR20220058655A (ko) 2022-05-09
RS58443B1 (sr) 2019-04-30
EP3120868B1 (en) 2020-04-08
CY1123089T1 (el) 2021-10-29
EP2172211B1 (en) 2014-12-03
KR101687840B1 (ko) 2016-12-19
EP3111952A1 (en) 2017-01-04
EP3120870B1 (en) 2020-04-01
CA2936887C (en) 2019-11-12
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
EP2331118B1 (en) 2016-10-26
TR201900852T4 (tr) 2019-02-21
CA2936868C (en) 2019-10-22
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
DK2172211T3 (da) 2015-02-16
HUE049364T2 (hu) 2020-09-28
CN102170901A (zh) 2011-08-31
LT3120869T (lt) 2020-11-10
KR102392070B1 (ko) 2022-04-29
PT3120869T (pt) 2020-09-22
EP2172212B1 (en) 2016-10-05
JP6294914B2 (ja) 2018-03-14
LT3069728T (lt) 2019-02-11
US20130004456A1 (en) 2013-01-03
ES2708654T3 (es) 2019-04-10
JP6367266B2 (ja) 2018-08-01
EA023013B1 (ru) 2016-04-29
EP3132801B1 (en) 2019-10-30
JP5855940B2 (ja) 2016-02-09
PL2341927T3 (pl) 2016-11-30
RS60386B1 (sr) 2020-07-31
EP3069728B1 (en) 2018-11-14
LT2331118T (lt) 2016-12-27
HRP20201015T8 (hr) 2022-01-21
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
CA2739387A1 (en) 2010-04-08
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
CA2936870A1 (en) 2010-04-08
JP2017029135A (ja) 2017-02-09
CY1123113T1 (el) 2021-10-29
KR101883426B1 (ko) 2018-07-31
US20160376317A1 (en) 2016-12-29
HUE051030T2 (hu) 2021-01-28
JP2014239681A (ja) 2014-12-25
DK2341927T3 (da) 2016-08-15
EP3106175B1 (en) 2020-04-01
ES2770090T3 (es) 2020-06-30
KR20160103558A (ko) 2016-09-01
CN102170900B (zh) 2016-10-26
PT2331118T (pt) 2017-02-06
CN106986919A (zh) 2017-07-28
US20100158931A1 (en) 2010-06-24
LT3111952T (lt) 2018-12-27
KR20180088494A (ko) 2018-08-03
US20210238227A1 (en) 2021-08-05
WO2010037514A3 (en) 2010-06-03
UA103202C2 (ru) 2013-09-25
US10919931B2 (en) 2021-02-16
RS60385B1 (sr) 2020-07-31
PT3111952T (pt) 2019-02-05
SI3124043T1 (sl) 2020-07-31
CA2936982A1 (en) 2010-04-08
HUE049366T2 (hu) 2020-09-28
JP2012504563A (ja) 2012-02-23
KR102133402B1 (ko) 2020-07-14
DK2331118T3 (da) 2017-01-09
HRP20170115T1 (hr) 2017-03-24
AU2009300088B2 (en) 2014-09-04
JP5883476B2 (ja) 2016-03-15
CY1123526T1 (el) 2022-03-24
PL2172212T3 (pl) 2017-04-28
CN102170900A (zh) 2011-08-31
PL3106175T3 (pl) 2020-08-24
US20160376316A1 (en) 2016-12-29
US10906936B2 (en) 2021-02-02
EP3111952B1 (en) 2018-10-31
SI3132801T1 (sl) 2020-03-31
EA201100586A1 (ru) 2011-10-31
ES2802226T3 (es) 2021-01-18
EA032437B1 (ru) 2019-05-31
US8653035B2 (en) 2014-02-18
PT2172211E (pt) 2015-03-09
LT2172212T (lt) 2016-11-10
US10227381B2 (en) 2019-03-12
ES2788129T8 (es) 2020-11-04
EP3124043A1 (en) 2017-02-01
DK3120870T3 (da) 2020-06-22
US20210253637A1 (en) 2021-08-19
RS60381B1 (sr) 2020-07-31
PL3111952T3 (pl) 2019-04-30
LT3106175T (lt) 2020-08-10
CY1123098T1 (el) 2021-10-29
JP6294913B2 (ja) 2018-03-14
JP2016145210A (ja) 2016-08-12
SI3120868T1 (sl) 2020-08-31
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
US20210347822A1 (en) 2021-11-11
JP2016047825A (ja) 2016-04-07
CA2739387C (en) 2019-10-29
ES2607460T3 (es) 2017-03-31
ES2710608T3 (es) 2019-04-26
HRP20150223T8 (hr) 2015-07-03
RS53782B1 (en) 2015-06-30
EP3069728A1 (en) 2016-09-21
JP6297632B2 (ja) 2018-03-20
HRP20200988T1 (hr) 2020-10-16
NZ591882A (en) 2012-12-21
HUE049367T2 (hu) 2020-09-28
ES2802227T3 (es) 2021-01-18
ES2819244T3 (es) 2021-04-15
CA2936887A1 (en) 2010-04-08
JP2017018102A (ja) 2017-01-26
PT3106175T (pt) 2020-07-01
AU2009300088A1 (en) 2010-04-08
AU2009300087B2 (en) 2014-09-04
HK1161106A1 (en) 2012-08-24
NZ591855A (en) 2012-11-30
BRPI0920791B1 (pt) 2022-01-18
US10941181B2 (en) 2021-03-09
CA2936982C (en) 2019-12-03
RS58229B1 (sr) 2019-03-29
SI3106175T1 (sl) 2020-08-31
DK3111952T3 (da) 2019-01-28
EP3132801A1 (en) 2017-02-22
HRP20201025T8 (hr) 2022-01-07
ES2804723T3 (es) 2021-02-09
HRP20200722T1 (hr) 2020-10-16
JP2012504393A (ja) 2012-02-23
SI3120869T1 (sl) 2020-10-30
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
CY1119744T1 (el) 2018-06-27
CY1122677T1 (el) 2021-03-12
LT3120868T (lt) 2020-08-10
CA2936920A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
DK3106175T3 (da) Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
HRP20150820T1 (en) Novel immunotherapy against brain tumors
EP2283418A4 (en) AUTHENTICATION WITH MULTIPLE FACTORS, MULTICANAUX
DK3195873T3 (da) Hidtil ukendt immunterapi mod flere forskellige tumortyper, herunder mave-tarm-cancer og mavecancer
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0912683A2 (pt) tratamento de tumores metastáticos
HK1156631A1 (en) Novel compounds and methods for therapy
AP2011005956A0 (en) Methods of treatment for solid tumors.
DK2094029T3 (da) Implanterbar transducer
BRPI0910854A2 (pt) métodos de tratamento
EP2330892A4 (en) TREATMENT PROCEDURE USING AMMONIA RECEIVER MEDICAMENTS
FR2933621B1 (fr) Sonde implantable
IL213344A0 (en) Methods for the preparation of aryl amides
DK2105501T3 (da) Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer
IL208918A0 (en) Methods of preparing substituted heterocycles-149
SE0702879L (sv) Sätt att framställa polyaluminiumföreningar
TH105556B (th) สารประกอบ และ วิธีการใหม่สำหรับการบำบัด
GB0818975D0 (en) Hair treatment methods
TH115925B (th) สารประกอบ แอริโลอะโซล-2-อิล ไซยาโนเอธิลอะมิโน ที่มีการเพิ่มอีแนนชิโอเมอร์มากขึ้น, วิธีการผลิตและวิธีการใช้สารนี้
TH0801002819A (th) สารประกอบที่กระตุ้นทีโลเมอเรส (Telomerase) และวิธีการของการใช้สิ่งเหล่านี้
UA18593S (uk) Аплікатор голчастий